Free tool
FAERS Monitor: Dayvigo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212028 or its brand name (Dayvigo, Lemborexant). Reports on generic versions are filed under their own applications.
Reports
2,946
Serious
2,287
78% of reports
Hospitalization
1,317
Death reported
370
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective332
- off label use215
- suicide attempt175
- condition aggravated157
- suicidal ideation156
- somnolence149
- fall111
- nausea104
- dizziness97
- headache97
- insomnia94
- adverse drug reaction92
- pyrexia91
- sleep paralysis88
- malaise86
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 199 |
| 2021 | 320 |
| 2022 | 376 |
| 2023 | 420 |
| 2024 | 554 |
| 2025 | 604 |
| 2026 | 469 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,213 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sleep paralysisSignal | 88 | 455.3 | 368.2 | 37,081 |
| suicide attemptSignal | 175 | 20.7 | 17.9 | 3,255 |
| suicidal ideationSignal | 156 | 12.2 | 10.5 | 1,595 |
| adverse drug reactionSignal | 92 | 7.3 | 6.0 | 497 |
| somnolenceSignal | 149 | 5.3 | 4.5 | 518 |
| condition aggravatedSignal | 157 | 3.7 | 3.2 | 309 |
| insomniaSignal | 94 | 2.5 | 2.1 | 86 |
| fallSignal | 111 | 2.4 | 2.0 | 89 |
| pyrexia | 91 | 1.9 | 1.5 | 37 |
| drug ineffective | 332 | 1.8 | 1.6 | 125 |
| off label use | 215 | 1.8 | 1.5 | 72 |
| malaise | 86 | 1.4 | 1.1 | 10 |
| dizziness | 97 | 1.4 | 1.1 | 10 |
| headache | 97 | 1.1 | 0.9 | 1 |
| nausea | 104 | 0.9 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.